Regeneron Pharmaceuticals, Inc.

Strong financial & commercial momentum (good) - Q2 2026 total revenue: +$17% YoY to $4.3B; non-GAAP EPS: +$11% YoY to $14.29 (GAAP EPS also up but affected by one-offs; net income $1.5B). - Free cash flow: $1.4B in 1H 2026; cash & marketable securities net of debt: $15.1B at quarter end. - Brand performance hitting new highs (key drivers): - Dupixent: $6B global net product sales (Sanofi-reported), +38% YoY (constant currency); management expects continued “long runway” via further indication penetration, age expansion, and international growth. - EYLEA HD (U.S.): ~$596M, +52% YoY and +27% QoQ; for first time, EYLEA HD sales exceeded EYLEA in the quarter. - Libtayo: ~$489M global, +29% YoY (constant currency); in U.S. 20% share of new-to-brand prescriptions in NSCLC.

Cash deployment: buybacks and operating investment; Sanofi collaboration step-up expected (opportunity + watch items) - Sanofi collaboration revenue: record $2.2B in Q2 (about $2.0B of that is Regeneron’s share of profits); share of profits +59% YoY due to improving margins and Dupixent growth. - Sanofi development balance fully repaid (approx. $3.1B when agreement amended); management says this reduces 2025/1H 2026 reported collaboration revenue via mechanical repayment effects. - Forecast implication: with full repayment starting Q3, Sanofi collaboration revenue is expected to “step up” going forward. - Capital return: $2.5B deployed in 1H (incl. repurchases/dividends/business development); $1.2B repurchased in Q2; ~2.4M net shares reduced since end of 2025; $2.5B repurchase authorization remaining. - Dividend mention: dividends included in 1H capital deployment (no new yield guidance provided in the transcript excerpt).

Pipeline catalysts: multiple major readouts and “near-term decision” expectations (opportunity) - Complement (gMG / cemdisiran): - FDA decision expected in November 2026 for cemdisiran (C5 siRNA) monotherapy in generalized myasthenia gravis; EMA decision expected in 2H 2027. - Regeneron also expects registrational PNH data in Q4 2026 for cemdisiran + pozelimab (vs ravulizumab; non-inferiority design vs eculizumab on co-primary endpoints). - Ocular GA: readout planned for 26-week exploratory data in Q4 2026 to inform pivotal strategy; strategy aims to avoid ocular safety issues seen with some therapies by systemic administration and exploring intravitreal optionality/co-formulations. - Oncology: - Lynozyfic (BCMAxCD3): LINKER-MM3 results expected 2027; additional 2028 expectations around MRD negativity in transplant-ineligible first-line and combination settings. - Ubamatamab (MUC16xCD3): promising monotherapy activity; detailed fall 2026 medical-meeting data expected (timing qualitative). - Obesity / obesity-plus-T2D: - Olatorepatide (GLP-GIP dual agonist, in-license): Phase III start later in 2026 in obesity and obesity+T2D; supportive competitive GI tolerability data highlighted.